Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

Michael Szarek, Vera A. Bittner, Philip Aylward, Marie Baccara-Dinet, Deepak L. Bhatt, Rafael Diaz, Zlatko Fras, Shaun G. Goodman, Sigrun Halvorsen, Robert A. Harrington, J. Wouter Jukema, Patrick M. Moriarty, Robert Pordy, Kausik K. Ray, Peter Sinnaeve, Sotirios Tsimikas, Robert Vogel, Harvey D. White, Doron Zahger, Andreas M. ZeiherPh Gabriel Steg, Gregory G. Schwartz, ODYSSEYOUTCOMES Investigators

Research output: Contribution to journal › Article › peer-review

132 Citations (Scopus)
44 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science